-

Concert Pharmaceuticals to Present at H.C. Wainwright Global Investment Conference

LEXINGTON, Mass.--(BUSINESS WIRE)--Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will participate virtually at the H.C. Wainwright 24th Annual Global Investment Conference, and its presentation will be available beginning at 7:00 a.m. ET on September 12, 2022.

The on-demand webcast of the presentation may be accessed in the Investors section of the Company’s website at www.concertpharma.com. A replay of the webcast will be available on Concert’s website for two weeks following the presentation.

About Concert

Concert Pharmaceuticals is a late-stage clinical biopharmaceutical company that is developing CTP-543, a novel oral JAK1/2 inhibitor. Concert has successfully completed two Phase 3 trials with CTP-543 in adults with alopecia areata, a serious autoimmune dermatological condition. The Company is also evaluating the use of CTP-543 in other indications and assessing a number of earlier-stage pipeline candidates. For more information, please visit www.concertpharma.com or follow us on Twitter at @ConcertPharma or on LinkedIn.

Contacts

Justine Koenigsberg
(781) 674-5284
ir@concertpharma.com

Industry:

Concert Pharmaceuticals, Inc.

NASDAQ:CNCE
Release Summary
Listen to Concert's on-demand webcast at the H.C. Wainwright Conference beginning at 7:00 am ET on September 12, 2022.
Release Versions
English
$Cashtags
$CNCE
Hashtags
#ConcertPharmaceuticals
#HCW
#HCWainwright
#InvestorConference

Contacts

Justine Koenigsberg
(781) 674-5284
ir@concertpharma.com

Social Media Profiles
Concert Pharmaceuticals LinkedIn
Concert Pharmaceuticals Twitter
More News From Concert Pharmaceuticals, Inc.

Concert Pharmaceuticals Maintains Deuruxolitinib Breakthrough Therapy Designation from FDA for the Treatment of Alopecia Areata

LEXINGTON, Mass.--(BUSINESS WIRE)--Concert maintains deuruxolitinib breakthrough therapy designation from FDA for the treatment of alopecia areata....

Sun Pharma to Acquire Concert Pharmaceuticals, Advancing the Potential Treatment of Alopecia Areata

MUMBAI & LEXINGTON, Mass.--(BUSINESS WIRE)--Sun Pharma to acquire Concert Pharmaceuticals....

Concert Pharmaceuticals Announces Presentation of Deuruxolitinib THRIVE-AA1 Phase 3 Study Results in Alopecia Areata During World Congress for Hair Research

MELBOURNE, Australia--(BUSINESS WIRE)--The presentation includes new analyses on the effect of baseline severity and duration of current episode of hair loss on scalp hair regrowth....
Back to Newsroom